Last reviewed · How we verify
The triamcinolone acetonide plus ropivacaine group
The triamcinolone acetonide plus ropivacaine group, marketed by Beijing Tiantan Hospital, holds a unique position in the pharmaceutical market with its combination therapy. A key strength is the extended patent protection until 2028, which helps maintain market exclusivity and revenue stability. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market expansion efforts.
At a glance
| Generic name | The triamcinolone acetonide plus ropivacaine group |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Preemptive Co-infiltration of Triamcinolone Acetonide With Ropivacaine for Postoperative Pain in Major Spinal Surgery (PHASE4)
- Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain (NA)
- Pre-emptive Scalp Infiltration with Triamcinolone Acetonide Plus Ropivacaine for Post-Craniotomy Pain in Children (PHASE4)
- Rhomboid Intercostal and Subserratus Plane Block Versus Paravertebral Block for Thoracic Herpes Zoster (NA)
- Triamcinolone Acetonide as an Adjuvant to Pre-emptive Scalp Infiltration for Relief of Post-craniotomy Pain in Adults (PHASE4)
- PRP vs Corticosteroid in Baker's Cyst (PHASE3)
- Project Arthritis Recovering Quality of Life Through Education - Hip (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |